Shanghai Qingrun Pharmaceutical Technology patents new Mat2A inhibitors

June 11, 2026

Shanghai Qingrun Pharmaceutical Technology Co. Ltd. has disclosed new S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors that are potentially useful for the treatment of cancer.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for June 22, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

Illustration of glucose in the blood stream

CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

BioWorld Science

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...

Saniona reports preclinical data for SAN-2668

BioWorld Science

Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...

Insilico Medicine synthesizes new Nav1.8 blockers

BioWorld Science

Insilico Medicine Inc. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain.